Algerian-German partnership agreement to produce hypertension, diabetes drugs


ALGIERS- A partnership agreement was signed Monday, in Algiers, between the Algerian-Turkish Abdi Ibrahim Remede Pharma (AIRP) and the German pharmaceutical company Boehringer Ingelheim for the local production of hypertension and diabetes drugs.


This €20 million agreement will consist in producing the medicines “Micardi.Plus” (against high blood pressure)  and “Jardians” (against Type 2 diabetes), said these two partners in the signing ceremony.

The production of these two medicines will be ensured by AIRP’s production plant in the new city of Sidi Abdallah (Zeralda).

According to the director general of Boehringer Ingelheim, Bachir Batel, the production of drugs to treat type 2 diabetes (Jardians) will start in the second quarter of 2019 and will be available in the second half of 2023.

The production of hypertension drugs will start once the technology transfer will be completed by April 2021, he said, underlining that it will be available in Algeria in the second quarter of 2021.

Concerning the price of these two medicines, he said that they will be marketed “at affordable prices.”

For his part, AIRP’s representative Mohamed Lamine Bousteila said investing €20 million in this project comprises equipment, technology transfer and training.






An Algerian news website aims at covering all the country’s territory through providing objective and positive image, focusing the most on breaking news.

A dynamic team is working on feeding the website by credible information in all fields of life; a reliable network composed of specialized elements working in harmony with our team in Algiers, the website’s headquarter, provides us more coverage and simultaneity.

“English” is what makes us different in Algeria and ranks us first too not only as a news website; English also makes it simple and fast for Anglophone world to discover our country.


Please enter your comment!
Please enter your name here